Krystal Biotech (FRA:4KB) Tariff Resilience Score: 8/10 (As of Jul. 01, 2026)


FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €330.30
GF Value €278.36
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech Tariff Resilience Score?

Krystal Biotech FRA:4KB +1.23% 58 Tariff Resilience Score is 8 as of Jul. 01, 2026. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €278.36 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,374 Biotechnology companies, Krystal Biotech ranks better than 98.69% on this metric.

Krystal Biotech has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Krystal Biotech has Krystal Biotech Inc benefits from the biotech sector's general tariff exemptions. Its operations are primarily domestic, reducing exposure to international trade policies. The company has not been significantly impacted by past tariff changes and can leverage its innovative products to maintain resilience.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Krystal Biotech might have Highly Resilient.

Krystal Biotech  (FRA:4KB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Krystal Biotech Tariff Resilience Score Related Terms

FRA:4KB vs TECH, SMMT, ARWR: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Krystal Biotech's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Krystal Biotech Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Tariff Resilience Score falls into.


FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Krystal Biotech (FRA:4KB) has a Tariff Resilience Score of 8 as of Jul. 01, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Krystal Biotech ranks #18 out of 1374 companies in the Biotechnology industry, placing it in the top 1.3%.
Is Krystal Biotech's Tariff Resilience Score too high?
Krystal Biotech's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. Krystal Biotech's value of 8 is 100% above this industry median. Based on the distribution chart, Krystal Biotech ranks #18 out of 1374 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Tariff Resilience Score compare to TECH and SMMT?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #18 out of 1374 companies for Tariff Resilience Score. This places Krystal Biotech in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Krystal Biotech's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €278.36, compared to a current price of €330.30 — trading 18.7% above its estimated fair value. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Tariff Resilience Score is 8 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €330.30 is trading 18.7% above its estimated GF Value™ of €278.36. GuruFocus considers Krystal Biotech to be Modestly Overvalued.

Key valuation signals for FRA:4KB:

  • Tariff Resilience Score: 8
  • GF Value™: €278.36 vs. price of €330.30 (18.7% above fair value)
  • GF Score™: 58/100 with 6 warning signs
  • Industry Position: 100% above the Biotechnology median (#18 of 1374)

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€330.30
Price
€278.36
GF Value